To the Editor We read with interest the recent article by Jackson et al1 in JAMA Oncology on aspirin (acetylsalicylic acid) therapy in patients with biliary tract cancer (BTC). The authors conducted a retrospective cohort study using data from the UK’s Clinical Practice Research Datalink (CPRD) to test the hypothesis that aspirin’s anti-inflammatory mechanism may slow the spread of BTC. Analysis of overall survival was stratified by aspirin prescription and BTC subtype. The results are impressive, with adjusted mortality hazard ratios ranging from 0.44 to 0.71, all statistically significant. Kaplan-Meier survival estimates showed that median overall survival was barely reached in the aspirin cohort. These results were interpreted to show that the survival benefit of aspirin is on par with the current standard therapy for BTC.1 We commend the authors on this innovative, thought-provoking research.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Bergquist JR, Shariq OA, Visser BC. Questionable Survival Benefit of Aspirin Use in Patients With Biliary Tract Cancer. JAMA Oncol. 2020;6(5):783–784. doi:10.1001/jamaoncol.2020.0122
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: